| Literature DB >> 18200824 |
Nasrin Perskvist1, Carl Söderberg, Marianne van Hage, Erik Edston.
Abstract
BACKGROUND: Intravenous injection of narcotic stimulants affects many cellular functions relevant for the pathophysiological mechanisms of heart failure. There is considerable evidence that mast cells (MCs), TNF-alpha, and cell death play crucial roles in the pathogenesis and progression of cardiac arrest. In this study, we examined and compared the participation of MCs, TNF-alpha, apoptosis and necrosis in the heart of drug-related fatalities and the victims of sudden death due to the cardiac failure or aortic dissection. METHODS ANDEntities:
Mesh:
Substances:
Year: 2007 PMID: 18200824 PMCID: PMC2350147
Source DB: PubMed Journal: Vasc Health Risk Manag ISSN: 1176-6344
Mean number of mast cell-subtype in the lung and heart sections of study subjects
| Explanatory parameters | Total area | SND | HLT | LLT |
|---|---|---|---|---|
| Bronchial MCs | 1.5 | 16.6 ± 1.2 | 31.3 ± 3.2 | 19.3 ± 1 |
| Parenchymal MCs | 1.5 | 11 ± 1 | 15.2 ± 1.2 | 13 ± 0.6 |
| Lung MCs | 3 | 27.6 ± 1 | 46.5 ± 2.2 | 32.3 ± 1.3 |
| Lung MCT | 3 | 5.6 ± 0.8 | 9.5 ± 1 | 5 ± 0.4 |
| Cardiac MCs | 3 | 12.8 ± 0.8 | 18.2 ± 2.8 | 17.6 ± 1.1 |
| Cardiac MCT | 3 | 0.5 ± 0.2 | 1.2 ± 0.9 | 1 ± 0.9 |
Abbreviations: SND, sudden natural death; HLT, high level of postmortal tryptase; LLT, low level of postmortal tryptase.
Note: Significant differences according to Kruskal-Wallis Test between three groups.
Data for the drug fatalities in HLT cases. Age, sex, and autopsy findings in drug fatalities with high levels of tryptase
| Case no. | Age/Gender | Heart weigh (g) | Recently injected drug | Other toxicological findings | Tryptase (μl/l) |
|---|---|---|---|---|---|
| 1 | 39/m | 312 | heroin | THC | 44 |
| 2 | 46/f | amphetamine | ethanol | 45 | |
| 3 | 36/m | 304 | amphetamine | benzodiazepines, THC | 46 |
| 4 | 29/m | 397 | heroin | amphetamine, THC | 48 |
| 5 | 31/m | 436 | heroin | benzodiazepines | 50 |
| 6 | 38/m | 434 | heroin | benzodiazepines, propoxyphene | 54 |
| 7 | 29/m | 292 | heroin | benzodiazepines, ethanol | 67.5 |
| 8 | 32/m | 335 | amphetamine | methadone, bensodiazepines | 71 |
| 9 | 36/m | 357 | heroin | amphetamine | 81 |
| 10 | 26/m | 400 | amphetamine | THC | 86 |
| 11 | 44/m | 390 | heroin | benzodiazepines, THC, ethanol | 90 |
| 12 | 35/m | 335 | methadone | benzodiazepines, THC | 240 |
| 13 | 24/m | 320 | heroin | amphetamine, cocaine, THC, benzodiazepines, stanozolol | 477 |
Abbreviations: THC, tetra-hydro-cannabinol (the active substance in hashish).
Data for the drug fatalities in LLT cases. Age, sex, and autopsy findings in drug fatalities with low levels of tryptase
| Case no. | Age/Gender | Heart weight (g) | Recently injected drug | Other toxicological findings | Tryptase (μl/l) |
|---|---|---|---|---|---|
| 1 | 24/m | 359 | heroin | benzodiazepines, THC | 5 |
| 2 | 26/m | 275 | heroin | benzodiazepines, cocaine, MDMA | 7 |
| 3 | 21/m | 394 | heroin | amphetamine, benzodiazepines, ethanol | 8 |
| 4 | 29/m | 304 | amphetamine | Ethanol | 9 |
| 5 | 21/m | 325 | heroin | Benzodiazepines | 10 |
| 6 | 21/m | 312 | heroin | benzodiazepines, ethanol | 11 |
| 7 | 51/m | 315 | heroin | benzodiazepines, THC, SRRI | 11 |
| 8 | 36/m | 335 | heroin | benzodiazepines, ethanol | 11 |
| 9 | 20/f | 231 | heroin | benzodiazepines, THC | 12 |
| 10 | 49/m | 410 | heroin | Ethanol | 13 |
| 11 | 30/m | 371 | amphetamine | benzodiazepines, THC, ethylmorphine | 14 |
| 12 | 25/m | 394 | heroin | benzodiazepines, THC, ethanol | 14 |
| 13 | 35/m | 408 | heroin | SRRI | 17 |
| 14 | 38/m | 361 | amphetamine | Tramadol | 18 |
| 15 | 27/m | 441 | heroin | MDMA, SRRI | 19 |
| 16 | 38/m | 430 | amphetamine | Cocaine | 22 |
| 17 | 26/m | 433 | heroin | metamphetamine, buprenorphine, SRRI | 27 |
Abbreviations: THC, tetra-hydro-cannabinol (the active substance in hashish); MDMA, 3,4-Methylendioxymetamphetamine (colloquially: Ecstasy); SSRI, Selective Serotonin Reuptake Inhibitor.
Data for the SND cases. Age, sex, and autopsy findings in 20 cases of sudden natural death
| Case no. | Age/Gender | Heart weigh (g) | Diagnosis | Tryptase (μl/l) |
|---|---|---|---|---|
| 1 | 52/m | 604 | AAD | 3 |
| 2 | 59/f | 363 | AMI | 3 |
| 3 | 54/m | 654 | AAD | 6 |
| 4 | 50/m | 440 | AVA | 6 |
| 5 | 40/f | 512 | HCM | 7 |
| 6 | 14/m | 312 | ARVD | 9 |
| 7 | 42/m | 370 | AMI | 9 |
| 8 | 47/f | 337 | AAD | 10 |
| 9 | 27/m | – | ARVD | 11 |
| 10 | 54/m | 364 | AMI | 11 |
| 11 | 45/m | 334 | MV PROLAPSE | 12 |
| 12 | 21/m | 389 | ARVD | 13 |
| 13 | 82/m | 621 | AVA | 13 |
| 14 | 42/m | 364 | AHF | 15 |
| 15 | 48/f | 318 | ARVD | 15 |
| 16 | 25/m | 323 | MYOCARDITIS | 15 |
| 17 | 49/m | 467 | AHF | 16 |
| 18 | 13/m | 284 | ARVD | 17 |
| 19 | 54/m | 610 | MYOCARDITIS | 17 |
| 20 | 48/m | 191 | ARVD | 21 |
Abbreviations: AHF, acute heart failure; AAD, acute aortic dissection; AVA, acute ventricular arrhythmia; ARVD, arrhythmogenic right ventricular dysplasia; AMI, acute myocardial infarction; MV, mitral valve; HCM, hypertrophic cardiomyopathy.
Figure 1(a) Dual immunostaining of anti-tryptase and -chymase in the same mast cell located within the interior wall of right ventricle. The insert: Cardiac mast cell staining only with anti-tryptase, MCT. (b) Mast cell degranulation in the heart section of a drug victim. Original magnification × 400, in A and × 200 in b.
Characterization of TNF-α, cell death and MCs degranulation in the heart of study population
| Study subject | Expression pattern of myocytic TNFα % Cases | Cell death | % Cases with MCs degranulation | ||||
|---|---|---|---|---|---|---|---|
| I | II | III | |||||
| SND (N = 20) | 10 ± 2.7 | 60 | 35 | 5 | 75 | 20 | 0 |
| HLT (N = 13) | 27.4 ± 5 | 15 | 0 | 84.6 | 23 | 30 | 77 |
| LLT (N = 17) | 34.5 ± 3 | 47 | 0 | 47 | 12 | 53 | 23.5 |
The mean number of granule-like structures of new synthesized intracelluar TNF-α.
≥3 apoptotic myocyte nuclei /HPF in a total area of 1 Cm2.
≥10 necrotic myocytes through an area of 1 Cm2.
I, Intracellular diffusely scattered pattern of TNF-αagranule-like structure.
II, Focal dense intracellular accumulation of TNF-α.
III, Focal, dense accumulation with an additional diffusely scattered intracellular distribution of TNF-α granule-like structures.
Figure 2Immunohistochemical analysis of TNF-α in endomyocardial tissues obtained from drug-related victims (a and c) and SND (b). Overview of transverse sections with cytoplasmic localization of newly synthesized myocytic TNF-α of pattern type I (a) and II (b). The longitudinal section (c) showing intracellular production of TNF-α of pattern type III in cardiomyocytes. TNF- α protein was also present in cardiac MCs (arrows). Analysis of TNF-α in longitudinal section of endomyocardial tissues obtained from a healthy control that died in unnatural causes (d). Original magnification × 200.
Figure 3Figure 3 (a) TUNEL-positive myocytes nuclei (brown) demonstrated with the ApopTag kit. The transverse section is from the left ventricle in a case of SND (× 200 magnifications). The insert: Higher magnification (× 400) of the same section showing complete labelling of myocytes nuclei. (b) Myocytic necrosis visualized by the binding of antibody against the terminal complement complex (purple) to the sarcolemma. The longitudinal is from the left ventricle in a case of LLT group (× 200 magnification).Insert: Higher magnification (× 400) of the same section showing immunoreactivity of cardiac myocytes to the C9-mab. The endothelium of intramyocardial vessels also reacted with C9-ab and used as an internal control (arrow).